AstraZeneca initiates Ph III comparison of Zactima and Tarceva
Anglo-Swedish drug major AstraZeneca says it has initiated a Phase III trial comparing its anticancer agent Zactima (ZD6474) with Roche's Tarceva (erlotinib), in the treatment of patients with locally-advanced or metastatic non-small cell lung cancer. The firm added that the program has begun enrolling patients at 160 sites worldwide, including 34 in the USA.
AstraZeneca said that the program, known as Study 57, is the first direct comparison of the two drugs in terms of progression-free survival benefit, in patients who have experienced a maximum of two prior failed chemotherapy regimens.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze